Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue of $24.8 billion, up 10.4% year-over-year, with operational growth of 11.6% Net earnings of $4.7 billion or $1.77 per share increased by 172%, exceeding the target that analysts had anticipated.
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2021 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported revenue of $24.8 billion, up 10.4% year-over-year, with operational growth of 11.6% Net earnings of $4.7 billion or $1.77 per share increased by 172%, exceeding the target that analysts had anticipated.
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2021 financial results before the regular market hours on Tuesday.
The pharmaceutical giant reported revenue of $24.8 billion, up 10.4% year-over-year, with operational growth of 11.6%
Net earnings of $4.7 billion or $1.77 per share increased by 172%, exceeding the target that analysts had anticipated.
